Envestnet Asset Management Inc. Grows Position in Phibro Animal Health Corporation $PAHC

Envestnet Asset Management Inc. lifted its holdings in Phibro Animal Health Corporation (NASDAQ:PAHC) by 97.3% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 24,334 shares of the company’s stock after buying an additional 11,999 shares during the period. Envestnet Asset Management Inc. owned approximately 0.06% of Phibro Animal Health worth $621,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently bought and sold shares of the business. Financial Management Professionals Inc. purchased a new position in Phibro Animal Health in the 2nd quarter worth approximately $32,000. National Bank of Canada FI acquired a new stake in shares of Phibro Animal Health in the first quarter valued at approximately $30,000. Yousif Capital Management LLC purchased a new position in Phibro Animal Health during the second quarter worth approximately $200,000. Quantbot Technologies LP boosted its stake in Phibro Animal Health by 53.8% during the first quarter. Quantbot Technologies LP now owns 7,870 shares of the company’s stock worth $168,000 after buying an additional 2,754 shares during the last quarter. Finally, Empirical Financial Services LLC d.b.a. Empirical Wealth Management acquired a new position in Phibro Animal Health during the first quarter worth $224,000. Hedge funds and other institutional investors own 99.34% of the company’s stock.

Analysts Set New Price Targets

PAHC has been the subject of a number of recent research reports. JPMorgan Chase & Co. raised their target price on Phibro Animal Health from $45.00 to $50.00 and gave the stock an “overweight” rating in a research note on Friday, November 7th. Bank of America lifted their target price on shares of Phibro Animal Health from $19.00 to $27.00 and gave the stock an “underperform” rating in a research note on Friday, August 29th. Zacks Research lowered shares of Phibro Animal Health from a “strong-buy” rating to a “hold” rating in a report on Monday, November 10th. Weiss Ratings restated a “buy (b-)” rating on shares of Phibro Animal Health in a report on Monday, November 17th. Finally, Morgan Stanley set a $34.00 price target on shares of Phibro Animal Health in a research report on Thursday, August 28th. Two equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, Phibro Animal Health currently has an average rating of “Hold” and an average target price of $31.40.

Insider Buying and Selling at Phibro Animal Health

In related news, CEO Jack Bendheim sold 5,280 shares of Phibro Animal Health stock in a transaction that occurred on Monday, November 17th. The shares were sold at an average price of $44.56, for a total value of $235,276.80. Following the completion of the transaction, the chief executive officer owned 54,960 shares in the company, valued at $2,449,017.60. The trade was a 8.76% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders have sold 144,776 shares of company stock worth $6,220,928 in the last 90 days. 50.13% of the stock is currently owned by corporate insiders.

Phibro Animal Health Stock Performance

NASDAQ:PAHC opened at $43.08 on Tuesday. Phibro Animal Health Corporation has a 52 week low of $16.16 and a 52 week high of $46.42. The company has a fifty day simple moving average of $40.69 and a two-hundred day simple moving average of $32.95. The company has a quick ratio of 1.25, a current ratio of 2.76 and a debt-to-equity ratio of 2.46. The company has a market cap of $1.75 billion, a price-to-earnings ratio of 36.51, a price-to-earnings-growth ratio of 1.24 and a beta of 0.81.

Phibro Animal Health (NASDAQ:PAHC) last released its earnings results on Wednesday, November 5th. The company reported $0.73 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.58 by $0.15. Phibro Animal Health had a return on equity of 32.14% and a net margin of 3.73%.The firm had revenue of $363.89 million during the quarter, compared to analyst estimates of $345.44 million. Phibro Animal Health has set its FY 2026 guidance at 2.640-2.810 EPS. As a group, equities analysts anticipate that Phibro Animal Health Corporation will post 1.95 earnings per share for the current fiscal year.

Phibro Animal Health Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 17th. Stockholders of record on Wednesday, November 26th will be given a dividend of $0.12 per share. The ex-dividend date of this dividend is Wednesday, November 26th. This represents a $0.48 dividend on an annualized basis and a dividend yield of 1.1%. Phibro Animal Health’s payout ratio is currently 28.92%.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.